Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Breakout day today... on the way to over $5 and up-listing to Nasdaq.
PR indicates All by the end of June. Then IMO expect FDA expanded approval IMO, then the way to $10 or acquisition by Big Med Equip mfg.
Hungry_Ghost...great post...
Here is a more challenging question regarding Brilacidin, as being the answer to Killing C-diff bacteria for which there is evidience that this bacteria is going from an infected small intestine (gut) through a leaky gut or other mechanisms to the brain...causing in some ALS, Parkinson's, Alzheimer and even MS...
Apparently evidence of linkage between UC/Chrones disease and the three or four named diseases...
Watch youtube video interview (link below) of Dr Jay Lombard, neurologist, by Dr. Mark Hyman, head of Functional Medicine at Cleveland Clinic.
If you dont want to watch it all...watch from the 47 minute mark. It is interesting...esp re to the CDC and how clueless they were about the issue of "leaky brain"...and infection from "leaky gut")
IPIX doesn't have to "step up"...or do "jack-sh*t"!
Increasing the anticipated enrollment from 106 to 138 in Russia...IMO signals where the most qualified patients candidates are robust and readily available...RUSSIA!
HereToday is IMO right on target...with U.S vaccines administered, the pool of candidates obviously has shrunk and it would be foolish for Leo to not take advantage of the greater and pool of qualified candidates immediately available in Russia...
As they say in a tennis match…"ADVANTAGE" IPIX...because the likely shift in numbers to Russia would represents a greater REDUCTION in TRIAL COSTS...since IMO it is at least 1/5th cost of U.S. patient enrollment/fulfillment.
FDA will have no issue, if scientific protocol is being adhered to …which appears is the case, since trials continue, after safety review.
So commentary..."IPIX hates spending money. something strange." is quite the opposite...IPIX is not "spending (more) money...Leo would be "Saving" money for IPIX with no impact on legitimacy of the C.T.
PS. last I checked...Gov Clinical Trial Registries in U.S. and Russia ARE PUBLIC...and if Leo was hiding the adjustment and if it were not already PUBLIC ... it would not be a matter of discussion on this board...
Stock Activity numbers are incorrect...not reflecting the number of IHUB investors correctly.
ICUSF...presents today at 2:45pm
22 Annual AMERICAN SOCIETY OF BREAST SURGEONS - Virtual Conference
Friday, April 30
2:45 PM -3:15 PM EDT Exhibitor Learning Sessions
IceCure Medical, Inc.: Cryoablation of Breast Tumors: Live Q&A
Join us to learn more about the technology and techniques of performing breast tumor cryoablation with Dr.
Richard Fine and Dr. Michael Berry of Margaret West Comprehensive Breast Center in TN and Dr. Susan A.
Seedman of the Ted and Margaret Jorgensen Cancer Center in NM. This live Q&A will include case studies
and a review of the recent ICE3 trial update.
https://www.breastsurgeons.org/meeting/2021/docs/asbrs21_agenda.pdf?v8
Seems as though you are worried about BP therapeutic competition.
Peter is absolutely correct:
"What possible blame can you find with IPIX for the slower than expected enrollment? Once the trial parameters and sites are fixed, things are completely out of IPIX hands."
It is easy to post: "It's not completely out of their hands as far as I can tell"... (ah...another Strawman setup!)
...without stating exactly what is in IPIX/LEO's "hands"...the statement is meaningless since once IPIX engages the U.S. Supervising CRO...CRO picks Clinical Trial Sites and sets thoses selected sites up, with their counter-part local CRO organization (if not in U.S.), then shipping exact and specified supplies set forth and approved by FDA in the protocal, then expediting the delivery of Brilacidin to the local CRO/Hospital site...then WAITING FOR PROSPECTIVE CANDIDATES, per protocal, and solciiting and selecting candidates with Hospital site Med Staff/Local CRO.
So wondering exactly where Leo/IPIX has control over expected enrollment and recruitment of candidates?
THE U.S. CRO runs the trials for IPIX....all sites report to and interact with the Supervising CRO...not LEO or IPIX... Supervising CRO reports on behalf of IPIX to ClinicalTrials.org as per direction and authorization of IPIX!
The pace of Clinical Trials is stricly "Patient Dependent", and not any patient, but Patient fitting the Clinical Trial Protocal of Moderate to Severe Covid-19 requiring hospitalization AND who have not taken the vaccine. In U.S. with millions taking the vaccines...millions are disqualified. Russian therefore becomes the obvious Site of Choice...if Protocaled Patients arrive first in Russia...
SO we are expected to believe that the U.S. Trial Supervising CRO LEAD does not have the appropriate company/executeve contact # and does not have Leo's cell phone to reach Leo 24/7?... IMO Beyond rediculous supposition.
And who has to speak Russian? Does anyone believe that Russian CROs could build a credible Western BP CRO business without boots on the ground local CRO not speaking English to their counterparts?*
In 1969, at 19, as a merchant marine, I was Leningrad (now St. Petersburg) and as I and other like-age guys disembarked from our ship, were met by a half a dozen Russians guys and women the same age, who wanted to buy our jeans, LP 45s, cigarettes etc...anything American. We ended up partying with them for two days...at 19-20 years old THEY SPOKE BETTER ENGLISH (including expressions) and knew more about the Yankees and U.S. culture than most to of the guys my age who were working on the ship.
"Go to India or Brazil!" some would say...ok, but by the time an expedited approval (120 days at best, in still highly Bureacratic (and corrupt) systems...) IPIX would be over, data in, analysis done and the FDA could have granted EUA...AND that wave in those countries could have be over, and new one starting in U.S. and Russia!!! (Exactly how long do the vaccines last/...no one knows)
It only takes a minute to understand that the suppositions put foward... "Not completely out of hands as far as I can tell" is without basis or common sense...
PS after much Russian vodka on both side...and their constant questions about the U.S and culture , I did ask if they were training to be spys ...of course, I got silence as a response.
You are confirming another reason (beside double-blinded) why there was not and could not be an "Interim Efficacy Analysis" in the Brilacidin-COvid-19 Clinical Trials. Just based on the CT design requested, and planned and inserted into the Protocol of the Clinical Trial APPROVED by the FDA...
You think?
There appears very little doubt that Brilacidin's Covid-19 Phase II Clinical Trials will result in a ...
David (IPIX) and Goliath (GILD) face off ...
...in the Double Blinded Clinical Trial of Brilacidin/Covid-19, where in the U.S. sites the SoC has been Remdesivir and Steriod combo...against which Brilacidin will be added.
Independent RBL test results indicate Brilacidin will outperform Remdesivir plus, upon mechanism for destroying Envelope viruses playing out in these CTs... These Clinical Trials IMO should yeild a big bonus with the destruction of other Enveloped Virus (*) , and in doing so, IPIX will be on its way in Clinically Confirming that Brilacidin has the mechanism to kill ALL enveloped PAN-CORONAVIRUSES and APLHA VIRUSES ... extending Brilacidin's value expotentially. not just against Covid-19 and its Variants. (The same Variants presently causing a new and deadlier waive...in younger people. (under 50)
From Company's lastest PR:
"Innovation Pharma is developing Brilacidin for COVID-19 under Fast Track designation from the U.S. Food and Drug Administration (FDA), and currently is enrolling patients in a Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Upon recently completing a scheduled review of interim safety data from the trial, an independent Data Monitoring Committee (DMC) recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which may maximize therapeutic benefits and provide a comparison with 5-day remdesivir (Veklury™), currently the only FDA-approved treatment for COVID-19. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
A peer-reviewed article in Viruses supporting Brilacidin’s COVID-19 treatment potential can be accessed at the link below.
· Bakovic, A.; Risner, K.; Bhalla, N. (et al). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses 2021, 13, 271; https://doi.org/10.3390/v13020271
https://www.mdpi.com/1999-4915/13/2/271 "
(*) AS NOTED BY DR. DEGRDO: *“It is a rewarding moment for me, as one of the discoverers of Brilacidin, to see Brilacidin continue to receive validation as a promising antiviral treatment—based both on in silico molecular modeling studies and lab research,” commented William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF), and Scientific Advisor for Innovation Pharma. “COVID-19 is, in all likelihood, here to stay. Bringing to market effective coronavirus therapeutics with novel mechanisms less prone to drug resistance developing due to mutations, a characteristic Brilacidin is exhibiting, will be important as the world combats this infectious and deadly virus. I look forward to seeing how Brilacidin performs in its Phase 2 trial in hospitalized COVID-19 patients and am hopeful Brilacidin will emerge as an effective antiviral, with added beneficial immunomodulatory properties.”*
Maxivest...the article you cite was well overdue ...
https://www.fdanews.com/articles/202455-advocacy-group-calls-for-rescinding-remdesivirs-approval-as-covid-19-treatment
Results of Brilacidin's Clinical Trials ... could be ...
"THE FINAL NAIL IN THE COFFIN?"...for REMDESIVIR (and the Gilead/Fauci/Big Pharma cabal).
...and make Brilacidin...the "last man standing"
Consider that in Brilacidin's Clinical Trials could or will, at some of the U.S. CT sites, go “head-to-head” with Remdesivir (as SoC). If the “BRILACIDIN Arm” demonstrates close to 100% viral reductions (as it did in RBL test results) and “Remdesivir Arm” ... demonstrates significantly less (30% reduction or even much less, as suggested by Advocacy Group that evidence point to Remdesivir as possibly worthless) ... the Fraud of Remdesivir will be well on its way to being confirmed.
Also as a Corollary...in the Russian C.T. Sites as well as the other U.S. non-Remdesivir SoC trial Sites, if the BRILACIDIN Arm demonstrates close to 100% viral reductions...and the non-Remdesivir SoC Arms, demonstrate less than 100% viral reduction ...then the CLINICAL TRIALS will have demonstrated Brilacidin would have been the only therapy/compound in the trial arms causing 100% viral reduction.
Of course...with a Biden/Susan Rice FDA and Dept of Justice...an investigation into the Gilead/Fauci cabal will likely be a "nothing to see hear!" response...and Gilead/Fauci will continue to reap their billions in ill-gotten gains...
IS THERE ANYONE DOUBT ... that BRILACIDIN IS A THREAT and could be a DIRECT HIT on Remdesivir? IMO ... "NO DOUBT!"
IMO...thank LEO for RUSSAIN CT and APPLICATION!
Jeremy is right...the US and TASE listings are tracking one another...US OTC exchange is trading at $1.00 the TASE listing is equivalent (after exchange rate) at $1.01....($.003069 * 329.7 = $1.0118493)
I agree...hardly enough shares out there for a need to do a reverse split...what for?
Going onto the Nasdaq with good revenue...company should want the float as noted...
...still looking for $10.00...$3-$4 upon uplisting $10.00 with FDA approval...then could see it being acquired shortly thereafter...
Yes Frenchie...almost as funny... So based on that statement, does that make Apple's virtual event...a Non-Event?
Its the "New Russian Hoax"...the IPIX version...questioning the quality of raw data accumulation Russian CT Sites... is an equivalent joke...
The FDA constantly passes and certifies Russian sites and practices. FDA makes regular inspections for quality and adherance to methods and protocols...which of course is why the major BP's constantly utilizes them for BP clinical trials.
Slowly accumulating more...on pullback...bought more during this orderly profit taking pull back ...should begin to reverse next week in anticpation of 4/30 presentation...IMO then march forward to over $2 and Nasdaq uplisting as previously announced was planned this quarter. Good FDA device approval...IMO = $10.00
Post sites article in Nature (journel) that states several "substances" with very low SI showed
"...several substances like Remdesivir, Lopinavir and Chloroquine were reported to repress viral replication in vitro. However, these compounds showed little effect on virus replication or led to severe adverse side effects in human patients." Bottom line: is that the in vitro assays in cells did not predict clinical behavior.
You noted...
Incorrect Statement: "Science is half of the success and management is the other half..." you forgot CAPITAL!
A Company can have:
1. the "Science" to prove out...and requires FDA approval in order to translate to Equity Value, (IPIX/Brilacidin)
2. They can have the "Management" to move it forward (Leo/DeGrado)...
3. but with no "Capital" ... nothing moves forward.
Without the Capital to move forward...the statement and/or suggestions that: "Follow the Money" is a MEASURE of Success or Failure at this stage of a drug development company is also an erroneous assertion based on a false assumption.
Without ALL three...the Science and product does not move forward. That was IPIX and Brilacidin...until 2020...
NOW...Leo has put the Third Leg on the stool...raised the capital for Brilacidin/Covid-19 AND other INDICATIONS...and has put BRILACIDIN in the bullseye of FDA.
SO THE PROCESS IS "FOLLOW THE SCIENCE"... "THEN FOLLOW THE MONEY"!
So right now... "Follow the Science"...
... which has been nothing but "STELLAR"...through RBL testing and giving it FDA recognition via Fast Track authorization and Investigational New Drug designation...leading to the CURRENT FDA CLINICAL TRIALS...
... listen to the PR and little birdies tweet "Alpha Viruses" and you will realize eyeballs are on Brilacidin for much bigger trophies than Covid-19 and its Variants...and
...wait for the Current clinical trial results...which dosing has been authorized to increase from 3 to 5 days of dosing to match Remdesivir protocol of 5 days and SoC in many U.S hospitals.
...THEN YOU CAN FOLLOW THE MONEY!!! (but of course, at a much greater price)
Upon demonstration in Phase II of success in disposing of ALL VARIANTS (since they are all Enveloped Viruses) and RBL testing showing high efficacy with ALPHA VIRUSES...
...IMO look for NOT "FOLLOW THE MONEY" ...but "CHASING THE MONEY" at over 20X, that is... $5.00 AS STARTERS and that's IMO a MINIMUN!
Biodoc…. YOU are right on…END OF STORY…
Apparently there were 109M shares issued and 72M shares in the float before the $15M private placement ($ needed to qualify for Nasdaq uplisting). Compnay issued/sold 93M shares @.16 to private placement investors...Private Equity, Hedge Fund and current Insider (likely CEO).
The 93M shares are likely Sec.144 shares locked up for 6 months, therefore not showing up in the 72M share float. (have not read filed docs...so don't know if warrants or options issued or available to Private Placement Investors.
Good deal for the new Private Placement investors... and ok for the new investors if FDA approval...the uplisting alone should bring in some institutional money...and eyeballs for acquisition possibilities.
Only negative is that they played with their announcment of Private Placement...noted "$15M DOLLARS" raised...but used Share Price .53 in NIS
(Israeli currency) which is equivalent to .1609 cents...IMO They tried to make it look like .533 cents ... deceptive move.
Yahoo reports 202.66M shares issued...71M in the float...LOW.
Difficult to buy with out running the SP up. I has a relatively wide spread (Bid/Ask). Took me weeks to accumulate 60K shares...
This should be a 10X bagger from $1.00 = $10.00 without any sweat, upon approval...
Yes a good one...we are asked to presume Dr. DeGrado, chair of DeGrado Labs at UCSF was "Brain Dead" coming back for an encore to support of Brialcidin at IPIX, and educate/promote his Brilacdin to the his friend Dr. Kessler, head of Operation Warp Speed, and also a professor with him at UCSF...as well as to the FDA..
...maybe they are both brain dead?...LOL.
or
...just maybe...They and others who are decision makers in FDA know more...LOTS MORE!
It certainly others have acknowledged DeGrado over 400 times with Awards and in Publications and have noted ... (as in one of his many Awards on the science surrounding Brilacidin)...
And in Winning the "INTERNATIONAL STEIN and MOORE AWARD" (2015) for his International Leadership and high impact research contributions (after Brilacidin)...in the field of Protein Science...
It was noted:
DeGrado’s research – spanning decades – focuses on small molecule and protein design as an approach to understanding macromolecule structure and function. He learned that proteins can be rationally designed in a staged modular manner based on simple chemical and conformational principles, and that both de novo and biologically-inspired functional elements can also be installed.
His work has also taught us the pitfalls in rational design, and has provided a battery of biophysical and biochemical methods that can be powerfully applied to validate and understand the structure of these designs. His pioneering work has shown that simple chemical principles can be rationally applied to highly complex systems to both understand them and create new materials and potential therapeutics.
The Stein and Moore Award is named for Nobel laureates Dr. William Stein and Dr. Stanford Moore. DeGrado will receive his award at the 29th Annual Symposium of The Protein Society on July 22-25, 2015 at Barcelona, Spain.
IMO...At IPIX...we are going to see the making of the next Nobel Laureate...demonstrate his discrovery, Brilacidin, play out in real life!
Now who are you going to listen too?
Forget about the flow of $ into our OTC stock right now...wait until after successful Clinical Trails demonstrating the leathal blow Brilacidin gives to this "ENVELOPE VIRUS"...
THE KEY MECHANISM of BRILACIN IS QUOTE: "POPPING THE ENVELOPE OF THE VIRUS AND BACTERIA...LIKE A PIN POPS A BALOON"....(400 Award Winning...Wm DeGrado, PhD formulator of Bricacidin)
Then look at the spectrum of "Envelope Viruses" which will be Brilacidin's MARKET...and what FLOW OF MONEY...will likely be coming IPIX's way!
Examples of enveloped viruses: ( https://en.wikipedia.org/wiki/Viral_envelope#Examples_of_enveloped_viruses )
The following are some examples of enveloped viruses:
DNA viruses
Herpesviruses
Poxviruses
Hepadnaviruses
Asfarviridae
RNA viruses
Flaviviruses
Alphaviruses
Togaviruses
Coronaviruses
Hepatitis D
Orthomyxoviruses
Paramyxoviruses
Rhabdovirus[2]
Bunyaviruses
Filoviruses
Retroviruses
Retroviruses
WHAT WILL THE FLOW OF $ and OFFERS BE?
Look at the common names of these viruses: https://en.wikipedia.org/wiki/Viral_envelope#Examples_of_enveloped_viruses
Setting up Strawmen to knock down with Blatently Faulse Assumption:
1. "now he barely has 30 participants and we're almost in May" due to the fact that IPIX could only recruit "barely" 30 "because no on will sign up"...blatantly false assumption.
FACT: Number of patients were required to be limited to comply with FDA protocol and go through safety interim check for 3 day dosing, before moving on to 5 day dosing AS PER PROTOCOL (see PR).
NOTE: 5 day dosing is SoC using Remdesvir ... Brilacidin/Covid-19 CT requires enough 5 day dosing for balance of trial to establish a number of 5 dosing patient group that would be statistical significant.
2. "now the FDA is saying higher dose because its ineffective". Blatantly False Statement
FACT: HIGHER DOSAGE indicated as the Protocol in Clinical Trial announcement PR where it was referenced that dosing would start with a 3-day dosing group, then a pause for safety check (DMC) then moving on to 5-day dosing. REQUIRED IN FDA PROTOCAL...WHICH MUST BE FOLLOWED" BY IPIX...and now we know it was.
NOTE: Brilacidin is a double-blind study...no knowledge by anyone of "efficacy" at this point and therefore conclusion
3. "There won't be trial results this year because no one will sign up."
Blatantly False Statement … for obvious reasons…
FACT: We are IN Clinical Trails for Brilacidin (Duh!) and announcement (PR) stated moving forward expeditiously…with IPIX received the Green Light for upping dosing to 5 day dosing.
NOTE: No factual basis for statement…PR = full steam ahead…
totally agree...
great news...ICU on its way. Could see this being $10 SP in the near future....
Dilution?...lol...IMO if you see dilution you will also see OM Phase III CT announcement (but likely see anyway without dilution)
MEANWHILE...LEO COMES THROUGH AGAIN!
...much info from PR.
1. 25% patients dosed for 3 days...now move expeditiously to complete trials with 5 day dosage (IMO had to stop 3 day dosing at 25% to be able to attain overall statistical significance for the 5 day regime)
2. Safety Profile passed with the 3 day regime...(IMO there was never a doubt).
3. Increase this week to 13 sites...to drive ahead quickly ("with variants" hitting those already vaccinated Covid 19 not going away any time soon"
NOTE IN PR: this reference AND it being a "worrisome reminder that SARS-CoV-2 isn’t going anywhere."
4. With the structure of Clinical Trial...REMESIVIR will not escape being exposed as virtually worthless in the Mod-Severe Patients.
PR NOTES: "The expanded dosing regimen has particular value in that a 5-day dosing is the recommended initial treatment duration for Gilead Sciences’ Veklury® (remdesivir), the only FDA-approved antiviral drug for treatment of COVID-19." When Brilacidin dosed patient shows 97%-100% viral load decline with Remedesivir Arm (SoC) and shows 97%-100% load reduction for "other" Arm (SoC)...Brilacidin will have shown its superior "killing" action over Remdesivir...
5. Brilacidin's Pan-coronavirus INDEPENDENT research continues...AND BEYOND!!!...in a positive direction (positive results not yet announced?)
PR NOTES: "More broadly, Brilacidin’s antiviral potency also appears to extend beyond coronaviruses to other types of viruses, based on independent ongoing laboratory research, further supporting Brilacidin’s broad spectrum antiviral potential.”
6. (Because of #5)...ONE OFF COMPETITORS...will be marginalized VS BRILACIDIN ("Holy Grail?")... What good is a Therapy that is a one trick pony (i.e. therapy only impacting the original Covid-19 or a variant)...It is REASONABLE to believe FDA/CDC must focus on finding and promoting not just a THERAPY that is "pan-coronavirus"...but a "PAN-VIRUS" THERAPEUTIC WHICH KILLS ALL CORONAVIRUSES...AND OTHERS! ... BRILACIDIN!
Agree with all the longs...we are overdue for news (overdue...thanks to FDA interim review process). I would, from the previous PRs that sequentially ... we should expect in next PR, re about trial dosage moving up from 3 to 5 day dosage...it could have occurred but Leo might not be reporting it yet...IMO we could hear this week, (but IPIX is always at the mercy of FDA on all events and reporting of them). But my expectation is that IPIX covid-19 CT will be done by end of April/Mid-May.
Patience..all in time... Vaccines are a "cluster-f***"...passport/no passport...a great deal of the population (including me) will not go near mRNA vaccines (or J&J).
IMO, therapeutic with Brilacidin's mechanisms (proven out, of course)is our only savior ( https://rumble.com/vdf68z-dr.-lee-merritt-interview.html )
That said, IMO Leo not just "waiting" ... I would not be surprised if news came out on OM phase III...imo, its ripe.
HOLY TOLEDO OF SPAIN!
Incorrect assumption: "106 of 120" (83%) WILL BE IN RUSSIA...BUT...it could be 106 of 150 patients entering the CT and dosed.
IMO IPIX will enter many more than 120 patients into its clinical trials and stop processing when 120 have fully completed the process and data transmitted by CRO.
Why would IPIX limit entry to ONLY 120 trial patients ?...Common sense (which Leo has shown he has a lot of...Hello Russia application) would dictate (and is done routinely) recruiting more than 120 and upon reaching 120 and fully processing and reporting on 120...they would stop and not complete the data transmission.
Reason for more than 120? Board readers need only contemplate "What if they can't reach a trial patient at 60 days (really between 50-70 days) from initial dosing?"
"Oh no...its exactly 60 days and we can't reach Dr. Tiab...our 120th patient, Oh no...we can never complete our trial! We are so screwed!"
A big RIDICULOUS LOL!
Clinical Trial CROs simply...move on the 20 or 30 extra patients being dosed in process ...
then, when the 120th patient's (the Extra Patient to account for the 120th patient) data is completed...TRIAL ENDS. 120 All LOCKED UP!
No single patient can sabotage the trials because IPIX doesn't have 120. Likely see close to 25% in the US and 75% in Russia...but those appear not to be hard numbers...(and FDA approved 120 wherever US or Russia or both! If the FDA is fine with them why should we care???) FDA has confidence in approving Russian sites...that is all IPIX needs.
"..Inclusion on the SRO list has nothing at all to do with any recent clinical trials."???
That sounds very conclusive...you can state what you wish...but do you have proof it has "nothing at all to do with recent clinical trials"?
GUARANTEE YOU DON'T!
If the trials did not "prompt" the qualification of IPIX (Brilacidin) on the SRO list...WHAT DID?
A DRUG QUALIFIES FOR THE FDA/SRO LIST..."... if its research, development, or other business activities are reasonably expected to result in the development of products that are regulated by FDA."
FDA IS STATING BY PLACING IPIX( BRILACIDIN) ON THE FDA/SRO LIST THAT ...
IPIX's "... research, development, or other business activities are reasonably expected to result in the development of (its) products "...BRILACIDIN!!!
It reasonably appears that this action is a direct result of the current review of the preliminary Clinical Trails...which is leading FDA to conclude ...that it is reasonable to expect IPIX's Brilacidin WILL RESULT IN ITS DEVELOPMENT AS A PRODUCT.
If it is not BECAUSE of the current Clinical Trials interim analysis or information the FDA has...then it is reasonable to conclude there is "OTHER" FDA action going on that has lead them to the conclusion that IPIX will result in the development of BRILACIDIN...which is even better positive news!
IPIS's INCLUSION ON THE FDA/SRO list ... appears to be a HUGE DEVELOPMENT indicating the positive developmentt (via clinical trials activities) of Brilacidin as a PRODUCT!
IMO BEST "NEWS" OF THE YEAR!...coming from the FDA
AND Massive Need and Massive Opportunity...for Brilacidin as an Effective Therapeutic..
IMO ...current Clinical Trials will demonstrate Brilacidin's mechanism displayed in RBL and espoused by Dr. DeGrado..., that is, Brilacidin will breach the Envelope Shell Structures of Covid-19 (and later the pan-coronavirus structures) ... Killing Covid-19 AND VARIANTS dead on contact.
...since ALL THE CURRENT VACINES... ARE BEING OUTSMARTED by COVID-19 Variants, as it changes into VARIANTS MORE DEADLY and MORE CONTAGIOUS...
RE-INFECTIONS ... in UK and BRAZIL...rendering Vaccinations USELESS...
Read on...
Virus Variants May Thwart Vaccines
March 18, 2021
A roundup of some of the latest scientific studies on the novel coronavirus...
Reuters
Multiple variants can “escape” vaccines
Antibodies induced by the Moderna Inc and Pfizer Inc/BioNTech SE vaccines are dramatically less effective at neutralizing some of the most worrying coronavirus variants, a new study suggests.
Researchers obtained blood samples from 99 individuals who had received one or two doses of either vaccine and tested their vaccine-induced antibodies against virus replicas engineered to mimic 10 globally circulating variants.
Five of the 10 variants were “highly resistant to neutralization,” even when volunteers had received both doses of the vaccines, the researchers reported on Friday in Cell.
All five highly resistant variants had mutations in the spike on the virus surface – known as K417N/T, E484K, and N501Y – that characterize a variant rampant in South Africa and two variants spreading rapidly in Brazil.
In keeping with previous studies, the proportion of neutralizing antibodies dropped 5- to 6-fold against the variants discovered in Brazil …
Variant identified in UK is deadlier
The coronavirus variant first identified in the UK, known as B.1.1.7, is deadlier than other variants circulating there, a new study appears to confirm.
Researchers analyzed data on 184,786 people in England diagnosed with COVID-19 between mid-November and mid-January, including 867 who died.
For every three people who died within four weeks after being infected with another variant, roughly five died after becoming infected with B.1.1.7, according to a paper posted on medRxiv ahead of peer review.
Overall, the risk of death with B.1.1.7 was 67% higher than the risk with other variants in England, the authors said…
Variant identified in Brazil is doubly infectious
Between November and January in Manaus, Brazil, the frequency of COVID-19 cases involving the P.1 coronavirus variant increased from non-existent to 73%.
Meanwhile, the number of infections there quadrupled compared to what the city experienced in the first wave of the pandemic, according to a report posted on medRxiv ahead of peer review …
Minnie...I concur with the reading of your tea leaves...
Good pick-up Longpicker...
Article supports desperate need for a Pan-coronavirus Therapy (LEO PR'd RBL's continue to investigage Brilacidin's Pan-coronavirus Therapy efficacies) ...which DeGrado believes Brilacidin has the mechanisms to be.
Sars-Covid viruses are "envelope" viruses...which Brilacidin is capable of bursting like a "Pin popping a baloon" on contact.
Under new revelations of more covid viruses are being discovered...and transmissable to the human race from animals...
Brilacidin could certainly be the "Holy Grail" if it proves to work as DeGrado believes it should.
NEW DANGERS ARE ALREADY HERE:
https://www.express.co.uk/news/science/1409329/Coronavirus-news-china-bat-disease-x-world-health-organisation-virus-pandemic-ont
SCIENTISTS have discovered a new bat virus in China which they believe to be 94.5 percent identical to COVID-19.
Researchers from Shandong First Medical University and Shandong Academy of Medical Sciences in Taian, China made the discovery in a regional bat. The World Health Organisation (WHO) has previously warned more diseases like COVID-19 can jump from animals to humans, calling the threat 'Disease X'.
In a stark warning, the Chinese researchers said RpYN06 was the closest disease to COVID-19 so far as it shares a similar spike protein.
The spike protein is the structure on the outside of the virus that it uses to bind to human cells.
So far, no other viruses found in bats or animals have had as similar a structure to SARS-CoV-2.
Over 300,000 are stuck on NHS waiting lists for more than a year
Shandong’s scientists looked at 411 samples collected from 23 bat species in Yunnan province in China during 2019 and 2020, and found four viruses related to SARS-CoV-2 were discovered.
In addition to RpYN06, the authors said in their paper “the other three SARS-CoV-2 related coronaviruses were nearly identical in sequence”.
Scientists, led by Weifeng Shi, then added “relatives of SARS-CoV-2 circulate in wildlife species in a broad geographic region of Southeast Asia and southern China”.
They said their findings “highlight the remarkable diversity of bat viruses”, but warned it is “essential that further surveillance efforts should cover a broader range of wild animals in this region to help track ongoing spill-overs of [viruses] from animals to humans”.
It follows virologist Chris van Tulleken warning another viral pandemic could be more deadly than the current COVID-19 epidemic.
Speaking on BBC Radio 4’s Today programme, he suggested the transmission of viruses from animals to humans are taking place more often than ever before.
He added: “It's not a question of if the next viral pandemic jumps, it's a question of when.
“And it's certainly possible to envisage a pandemic that will be far more severe in some ways than our current experience.”
THE CPA CANARD! Totally disagree with your analysis...it is a total non-issue!
Leo referencing himself as a CPA (a designation granted by a State) is appropriate, in this context. He is not alleging himself to be or implying that he is CPA for the IPIX or actively practicing as a CPA anywhere. As he is a former practicing CPA (and if I recall, it has been in the Public Company areana), it is not unreasonable to assume he has a depth of knowledge which makes him eminently qualitified to be both CEO and CFO (neither of which would require him to be a registered/licensed CPA). Also, one cannot call oneself a CPA without having been so designated by a licensing state...(taking and passing testing vs. graduating with a degree in accounting) and having been so designated does "indicates that he attained a high degree of proficiency in accounting."
Using his "knowledge" as a CPA in his postion as CEO and CFO does not constitute "unlicensed practicing" as a CPA. THEREIN LIES THE DISTINCITON...and "NITPICKING" to an incorrect position and conclusion.
It is NOT UNLIKE an ATTORNEY who retires. If an Attorney has "retired" (volunatarily and was not disbarred) he may still generically (having a education in law) refer to himself as an Attorney, but he cannot any longer hold himself out as an Attorney "Practicing Law". As with LEO, a "retired" Attorney may apply for reinstatement to "Actively" practice as an Attorney (as Leo could do if he wanted to "practice" as a CPA), vs. an attorney or CPA who has had their licenses REVOKED.
BOTTOM LINE...While Leo refers to himself as a CPA, he does not state he is "practicing" as a CPA, nor acting as CPA for IPIX...but simply is a CPA...
ps a more on point case involves Sen Elizabeth Warran...a leader of "truth, justice, intergrety and the America way!" NOT! https://elizabethwarrenwiki.org/massachusetts-bar-controversy/
SHE has actually pulled all political strings to hold back the assault and prosecution for her actual unlicensed "Practicing of Law" in MA without not only a license there, but having had her previous licenses "revoked" in TX (which license she used to qualify for her Harvard Law Professor position) and NJ (after never having one in MA)...then claiming her filing of an Amacis Brief was not practicing law because she had no client.
https://www.nationalreview.com/the-campaign-spot/elizabeth-warren-unlicensed-lawyer-jim-geraghty/
Also clever how SLATE changes the entire issue, as though she is attacked for the kind of clients she represented and her fee structure...not that she had no license when representing them.
volune good...why should it trade briskly without more news? everything pivots on results of Trial..
SP holding up very well...all holder...bodes well for $20 on good news...TO START
Score +1 for Brilacidin/Ipix Score -10 for EIDD-2801/Ridgeback
I have been just alerted by a DR. (and former Medical Reseach Fellow) who is a Poster on this board...that Ridgeback could become quite a earthquake of a disaster...for its promoters...
read on...there are serious MUTATION issues outstanding with RIDGEBACK RNA EIDD-2801...
"More on Ridgebacks EIDD-2801:"
"..Also in March, DRIVE found a new partner in Ridgeback, a small, privately held company founded by husband and wife Wayne Holman and Wendy Commins Holman, that is best known to infectious disease scientists for licensing an experimental monoclonal antibody that worked well against the Ebola virus in a clinical trial. (That treatment was developed by the National Institute of Allergy and Infectious Diseases.) Ridgeback purchased an exclusive license to EIDD-2801 from DRIVE for an undisclosed amount.
Raymond Schinazi, an Emory University chemist who has extensively studied the active ingredient in EIDD-2801 but has no connection to DRIVE, notes that his former pharmaceutical company, Pharmasset, abandoned it in 2003 after discovering its mutagenic properties. Schinazi says the small chemical tweaks made to increase the ingredient’s bioavailability and transform it into EIDD-2801 are unlikely to (lower) change its mutagenicity. “Thank goodness someone is raising the red flag,” about EIDD-2801, Schinazi says. “You don’t develop a drug that’s mutagenic. Period.”
https://www.sciencemag.org/news/2020/05/emails-offer-look-whistleblower-charges-cronyism-behind-potential-covid-19-drug
But the POSITIVE SIDE for BRILACIDIN...
IPHARMA (a CRO who has been identified on this board as IPIX CRO in RUSSIA) is a well-established CRO that manages clinical trials in Russia and EAEU. Clinical branch of ChemRar group, and partner of Skolkovo Innovative center.
ChemRar is a major Pharmaceutical company in Russia and with whom the Russia invests and collaborates in commercial ventures...
CAN ChemRar, intimate with Brilacidin via their CRO arm, IPHARMA, along with the Russia Direct Investment Fund (RDIF) BOTH of whom joint ventured and INVESTED AND FUNDED THE SOC IN RUSSIA, Avifavir (favipiravir) become IPIX's Partner in Eastern EU and the Russian Federation?
READ ON.... https://en.chemrar.ru/chromis-published-results-of-a-multi-center-open-label-post-marketing-clinical-study-in-940-covid-19-patients-confirming-efficacy-of-avifavir-at-croi2021/
"Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner Viriom Inc., a San Diego CA-based biotech reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic Infections CROI2021."
I also found a 10 year old post by MinnieM (f/k/a/...) discussing an interesting Russian Pharmacuetical/Investment company...ChemRar which collaborates with Pfizer and the RUSSIAN
MinnieM Member Level Wednesday, 06/29/11 02:31:05 PM
Re: None 0
Post #
358
of 3258
PFE - Pfizer and ChemRar High Tech Center Announce Plans to Explore Innovative Medical Research and Development Partnership in Russia.
http://ih.advfn.com/p.php?pid=nmona&article=48251290&symbol=PFE
Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) announced today that they have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries. The announcement was made during the BIO International Convention.
The two companies will explore opportunities for accelerated development and commercialization of certain innovative compounds from Pfizer’s pipeline, through technology transfer and out-licensing deals with venture funding. Through this arrangement, Pfizer and ChemRar plan to develop innovative compounds and vaccines to treat patients with cardiometabolic, infectious and oncology diseases, which are a high priority for the Russian Federation healthcare system.
Under the terms of the MoU, the two companies can further collaborate with other potential partners, including the Moscow Institute of Physics and Technology, the Skolkovo Foundation and other members of the Russian Biopharmaceutical Cluster “Northern,” created under the Federal Target Program of the Ministry of Industry and Trade of the Russian Federation. In addition, the companies can establish a shared-risk platform for several Pfizer R&D programs designed to achieve clinical candidates and proof of concept in the clinic.
“We see Russia as a potential leader in the innovative pharmaceutical, biotechnological and nano-technological areas,” said David Simmons, President and General Manager, Emerging Markets and Established Products, Pfizer. “The Pharma 2020 Strategy driven by the Russian Government creates favorable conditions for transition of the Russian pharmaceutical industry to the innovative development model, and Pfizer is excited to be a part of these new opportunities.”
“Considering the importance of international partnership to our Government’s vision for Russian business, the expertise of leading pharmaceutical companies such as Pfizer is very important. Agreements such as this are critical to developing the applied sciences and university research in Russia, within the global market environment. We hope our partnership will also help create a belt of small innovative businesses within the Biopharm Cluster “Northern” initiative created under the auspices of the Moscow Institute of Physics and Technology and fully supported by the Ministry of Industry and Trade of the Russian Federation,” says Andrey Ivaschenko, Chairman of the Board, ChemRar.
To expedite cooperation Pfizer and ChemRar will create an Expert Committee, which will include specialists with a high level of experience and expertise.
The partnership with ChemRar is an important component of Pfizer’s broader strategy in Russia named “MORE THAN,” which is designed to contribute to the modernization of the national healthcare system, extended life-expectancy, lowered mortality rate and a better quality of life for all Russians. More Than is designed to create value for the Russian people through progressive partnerships aimed at the modernization of the pharmaceutical industry, accelerating the development of medical innovations, and improving access to medicines and better healthcare.
As part of its investment strategy in Russia, in March 2011 Pfizer announced the agreement with Russian biopharmaceutical company Petrovax Pharm to manufacture Pfizer’s innovative pneumococcal vaccine in the Moscow region, as well as the June 2011 launch of the capability building program MORE THAN EDUCATION in partnership with Saint-Petersburg, St. Petersburg State Chemical-Pharmaceutical Academy and the Russian biotechnology company Biocad. Pfizer and its partners look forward to contributing to the creation of medical innovations, further modernization of the Russian pharmaceutical industry, improving the national healthcare system and delivering better health and quality of life to Russian citizens.
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
To learn more about our commitments, please visit us at www.pfizer.com and www.pfizer.ru.
About ChemRar
Non-commercial partnership ChemRar High Technology Center is a unique complex of research, production and investment facilities operating in the fields of development and commercialization of innovative medicines for treatment of cardiovascular diseases, endocrinology, infectious diseases, oncology, and CNS diseases both in Russia and abroad.
ChemRar Ventures is a Russian venture company managing the diversified portfolio of investment into innovative biotechnological and biopharmaceutical companies.
www.chemrar.ru
About BPC “Severny”
Biopharmaceutical cluster “Severny” is an association of the Moscow Institute of Physics and Technology with small innovation companies operating with the support of the Ministry of Industry and Trade of the Russian Federation, Moscow Region Government, Administrations of the cities of Dolgoprudny and Khimki. BPC aims at the creation of a belt of small innovation enterprises and corporate laboratories around the Moscow Institute of Physics and Technology in the field of “living systems”. Apart from High Tech Center ChemRar and the Moscow Institute of Physics and Technology, BPC includes such companies as “Akrikhin”, “Pharmstandart”, GC “Protek”, FGUP NPTs “Pharmzaschita”, etc.
www.pharmcluster.ru
PFIZER DISCLOSURE NOTICE: The information contained in this release is as of June 29, 2011. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about a Memorandum of Understanding (“MoU”) between Pfizer and ChemRar and Pfizer’s strategy in Russia, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, whether and when Pfizer and ChemRar will enter into a definitive agreement establishing a collaboration, as well as the risks and uncertainties inherent in research and development, including whether and when any drug application will be submitted in Russia for any potential product candidates, decisions by regulatory authorities in Russia regarding whether and when to approve any such potential drug applications as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; competitive developments; general economic, political, business, industry, regulatory and market conditions; and the other risks and uncertainties set forth in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6777824&lang=en
And, of course, some contend that...
Dr. Kessler of UCSF and now at OPERATION WARP SPEED (charged, with supporting the development of Covid-19 therapies) ... would not have a professional relationship with Dr. Wm DeGrado of UCSF (co-founder/developer of Brilacidin under clinical trails for Covid-19.)
But as Scientific Advisor to IPIX...IMO both would be of assistance in recognizing and assisting IPIX's efforts in supporting Brilacidin into the market (of course assuming successful CT)
Also...DeGrado himself ("WITH A LITTLE HELP FROM MY (HIS) FRIENDS!")...can't be overlooked as one of IPIX's greatest assets in bringing Brilacidin forward...
Below is a list of Students receiving ADVANCED DEGREES under DR. WM. DEGRADO since (and before) formulation of Brilacidin while at University of Pennsylvania ...
...would they have not accomplished professional advancements...see for yourself!
For those who would say "NOTHING HERE!"
WRONG AGAIN...IMO Dr. DeGrado throught the UCSF "DeGrado Lab" has planted and spouted many significant professionals ... IN INFLUENTIAL POSITIONS...in BOTH BP and the FDA!
WHO ON THIS LIST OF STUDENTS...might be of great assistance to DeGrado, Brilacidin and IPIX??? (maybe even greated than IMO his associate, Dr. Kessler?)
DeGrado Lab
Research laboratory of William DeGrado, PhD
Alumni
Postdoctoral scholars
Name Years Current position
Susan Erickson-Viitanen 1984–1986 Senior Director, Incyte Corporation
Siew Peng Ho 1986–1988 Senior Principal Scientist, Bristol-Myers Squibb
Lynne Regan 1986–1988 Professor, Yale University
Normand Voyer 1986–1988 Professor, University of Laval (Quebec)
Tracy Handel 1988–1991 Professor, University of California, San Diego
Rob Fairman 1990–1993 Professor, Haverford College
Spencer Anthony-Cahill 1990–1993 Professor, Western Washington University
Karin Akerfeldt 1991–1994 Professor, Haverford College
Dan Raleigh 1991–1994 Professor, SUNYSB
Steve Betz 1993–1996 Vice President, Biology at Crinetics Pharmaceuticals
Jim Bryson 1994–1996 EX. Director, Bristol Myers Squibb
Helen Lu 1994–1999 Researcher, DuPont Central Research
Daniel Suich 1994–1998 Cell Biological Science, Palo Alto, CA
Guillermo Morales 1995-1997 Director of Scientific Services, Cogent Professionals
Richard Cheng 1995–2002 Professor, National Taiwan University
Gregg Dieckmann 1995–2000 Associate Professor, University of Texas at Dallas
Blake Hill 1995–2000 Professor, Medical School of Wisconsin
Joel Schneider 1995–2000 Director, NCI
Giovanna Ghirlanda 1996–2002 Professor, Arizona State University
David Salom 1996–2000 Senior Scientist, Polgenix / Case Western Reserve University
Zelleka Getahun 1998-2000 Regulatory Review Chemist, FDA
Paul Dalby 1998-2000 Professor, University of London
Dahui Liu 1999–2003 Chemistry Reviewer, FDA
Herschel Wade 2000–2006 Associate Professor, Johns Hopkins University
Michael Rosenblatt 2000–2003 Group Leader, Promega
Gregory Tew 2000–2001 Professor, U Mass Amherst
Renhao Li 2001–2005 Professor, Emory University School of Medicine
Vikas Nanda 2001–2005 Professor, Rutgers University
Seth Snyder 2002–2004 Patent Agent, Dechert LLP
Lidia Cristian 2002–2005 Program and Alliance Manager, Drug Discovery Applications Group, Schrödinger
Frank Cochran 2002–2005 Scientific Staff, Stanford University
Lars Gerlach 2003–2004 Executive Vice President R&D at EpiTherapeutics
Catherine Goodman 2003–2006 Associate Editor, Nature Chemical Biology
Kenichi Kuroda 2003–2006 Associate Professor, University of Michigan
Jen Cochran 2004–2005 Professor, Stanford University
Alessandro Senes 2004–2008 Associate Professor, University of Wisconsin-Madison
Chad Tatko 2004–2006 Associate Professor, Calvin College
Hubert Yin 2004–2007 Professor & Deputy Dean, Tsinghua University
Shalom Goldberg 2004–2010 Senior Scientist, Centyrex, Johnson & Johnson
Karen McAllister 2005–2006
Chris Fry 2005–2007 Scientist, Argonne National Laboratory
Bryan Berger
2005–2009 Associate Professor, University of Virginia
Greg Caputo 2005–2007 Professor, Rowan University
Ting Xu 2006–2006 Professor, UC Berkeley
Ilan Samish 2006–2010 CEO, Amai Proteins
Soni Basra 2006–2007 Patent Attorney Candidate, df-mp (Germany)
Amanda Reig 2006–2009 Professor, Ursinus College
Cinque Soto 2006–2011 Vanderbilt University, Associate Professor
Rudresh Acharya 2006–2011
Assistant Professor, School of Biological Sciences, NISER
Ivan Korendovych 2006–2011 Associate Professor, Syracuse University
Jade Qiu 2007–2012 Associate Professor, Soochow University in China
Jason Donald 2007–2011 Head of Design, Manus Bio, Inc.
Jon Rudick 2007–2010 Associate Professor, Stony Brook University
Anjali Ganjiwale 2007–2009 Scientist, Institute of Bioinformatics and Applied Biotechnology (IBAB), Bangalore, Karnataka, India
Gevorg Grigoryan 2008–2011 Associate Professor, Dartmouth College
Patrik Nygren 2009–2010 Senior Research Scientist, Rational Enzyme Mining AB
Jenny Hu 2009–2014 Staff Scientist, Schief Lab, Scripps Research Institute
Craig Streu 2009–2011 Associate professor, Albion College
Marcos Pires 2009–2011 Associate Professor, Lehigh University
Nathan Joh 2009-2015 Scientist, Amgen
Brooke Rosenzweig 2010–2011 Program Manager, Mount Sinai School of Medicine
Belgin Canturk 2010–2012 Senior Chemist, Dow AgroSciences
Michelle McCully 2012–2016 Assistant Professor, Santa Clara University
Reza Malmirchegini 2013–2016 Biophysical Analytical Scientist, Revance Therapeutics
Manasi Bhate 2013-2017 Scientist II, DuPont/Genecor
Gozde Ulas 2012-2017 Scientist, Genentech
Mimi Nick 2013-2016 Upper School Biology Teacher, Charlotte Latin School
Thomas Lemmin 2013-2017 Postdoctoral fellow, ETHZ
Sungkyu Park 2016-2017
Shao-Qing Zhang 2016-2018 Principal Investigator, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences
Nathan Schmidt 2015-2018 Protein Engineer, Ginkgo Bioworks
Bobo Dang 2015-2019 Assistant Professor, Westlake Institute for Advanced Study
Jack Nicoludis 2018-2019 Computational Biologist, Invitae
Haifan Wu 2016-2020 Assistant Professor, Wichita State University
Graduate students
Name Years Current position
Karyn O'Neill 1992–1998 CSO, Centyrex Venture, Johnson & Johnson
Chris Summa 1996–2002 Associate Professor, University of New Orleans
Wai Lau1996–2004 Staff Scientist, Bristol-Myers Squibb
Scott T. Walsh 1997–2000 Staff Scientist, NCI
Holly Gratkowski 1998–2002 Associate Director, Bracket
Avram Slovic 1999–2004 Managing Director, AgVali, Brazil
Jen Calhoun 2001–2007
Amanda Stouffer 2001–2007 Principal Scientist in Discovery Technologies, Roche Pharmaceuticals,
Ben North 2001–2006 Research Scientist, Fox Chase Cancer Center
Rachel Signarvic 2001–2007 Adjunct Professor, Rowen University
Sungwook Choi 2002–2006 Assistant Professor, GSDD at Chungnam National University
Don Engel 2002–2006 Assistant Vice President for Research, Affiliate Professor of Physics and Computer Science UMBC
Douglas Metcalf 2002–2009 Associate, Foley Hoag, LLP
Joanna Slusky 2002–2008 Assistant Professor, University of Kansas
Gretchen Bender 2003–2008 Senior Analyst, PriceSpective, LLC
Scott Shandler2003–2009 CEO, Longevity Biotech
Alexei Polishchuk 2004–2009 Resident Physician in Radiation Oncology, UCSF
Dave Moore 2004–2010 Assistant Professor, Department of Psychiatry, Yale medical School
Dan Kulp 2005–2009 Associate Professor, Wistar Institute
YongHo Kim
2005–2011
Assistant Professor, Sungkyunkwan University
Meredith Miller
2006–2008
Anesthesia Specialist, Beth Israel Deaconess Medical Center
Yao Zhang 2006–2011 Director of Emerging Portfolio Strategy, AstraZeneca
Jun Wang 2006–2014 Assistant Professor, University of Arizona
Geronda Montalvo 2007–2012 Sr. Scientist, Merck
Graham Clinthorne 2007–2012 Medical Writer, MediTech Media
Brett Hannigan 2008–2013 Computational Biologist Project Leader,DNAnexus
Gabriel Gonzalez 2009–2013 Software Engineer, Twitter
Chaim Schramm 2010–2012 Staff Scientist, Vaccine Research Center, NIAID, NIH
Kathleen Molnar 2007–2015 Research Scientist, ViewPoint Therapeutics
Jessica L Thomaston 2011–2018 Postdoc, Trinity College Dublin, Marie Curie Fellow
Marco Mravic 2014–2020 Scripps Fellow, Scripps Research Institute
Certainly guidence from Dr. DeGrad, the founder/developer of Brialcidin and IPIX's Scientific Advisor, with years of experience and knowledge of the mechanics and science of Brilacidin is huge...
But IMO the DeGrado - Kessler (OWS) relationship is real, strong and could be pivotal going forward...also rumblings that even stronger connections likely exist and that IPIX/Brilacidin is quietly but firmly in top decision makers bullseyes...
...of course how it all plays out and the ultimate success/failure all depends upon Clinical Trials results...but our "indendent" verification (vs internal self-serving Husband/Wife "claims" for other candidates) bodes extremely well for Brilacidin/Covid-19 high efficacy, ESPECIALLY COVERING ALL VARIENTS OF COVID-19.
Yes...Brilacidin Clinical Trails continue...
IMO ... disregard faulty analysis...as to duration of trials: